BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17855704)

  • 1. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer.
    Albert JM; Gonzalez A; Massion PP; Chen H; Olson SJ; Shyr Y; Diaz R; Lambright ES; Sandler A; Carbone DP; Putnam JB; Johnson DH; Lu B
    Cancer Epidemiol Biomarkers Prev; 2007 Sep; 16(9):1845-51. PubMed ID: 17855704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
    Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
    Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.
    Shinohara ET; Gonzalez A; Massion PP; Chen H; Li M; Freyer AS; Olson SJ; Andersen JJ; Shyr Y; Carbone DP; Johnson DH; Hallahan DE; Lu B
    Cancer; 2005 Apr; 103(8):1685-92. PubMed ID: 15742356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
    Graziano SL; Tatum AH; Gonchoroff NJ; Newman NB; Kohman LJ
    Clin Cancer Res; 1997 Jan; 3(1):87-93. PubMed ID: 9815542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
    Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
    J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients.
    Ferreira CG; van der Valk P; Span SW; Ludwig I; Smit EF; Kruyt FA; Pinedo HM; van Tinteren H; Giaccone G
    Clin Cancer Res; 2001 Aug; 7(8):2468-74. PubMed ID: 11489828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
    Yanagisawa K; Tomida S; Shimada Y; Yatabe Y; Mitsudomi T; Takahashi T
    J Natl Cancer Inst; 2007 Jun; 99(11):858-67. PubMed ID: 17551146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
    Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of immunohistochemical Rac1 expression in survival in early operable non-small cell lung cancer.
    Yuan K; Qian C; Zheng R
    Med Sci Monit; 2009 Nov; 15(11):BR313-9. PubMed ID: 19865048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between survivin expression and prognosis in non-small cell lung cancer.
    Atikcan S; Unsal E; Demirag F; Köksal D; Yilmaz A
    Respir Med; 2006 Dec; 100(12):2220-6. PubMed ID: 16650973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of polysialic acid expression in resected non-small cell lung cancer.
    Tanaka F; Otake Y; Nakagawa T; Kawano Y; Miyahara R; Li M; Yanagihara K; Inui K; Oyanagi H; Yamada T; Nakayama J; Fujimoto I; Ikenaka K; Wada H
    Cancer Res; 2001 Feb; 61(4):1666-70. PubMed ID: 11245481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
    Yilmaz A; Ernam D; Unsal E; Demirag F; Atikcan S; Taştepe I
    Arch Med Res; 2007 Oct; 38(7):764-8. PubMed ID: 17845896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
    Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
    Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
    Zhang Z; Ma J; Li N; Sun N; Wang C
    Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
    Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
    Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The evaluation of prognostic value of cyclin B1 expression in patients with resected non-small-cell lung cancer stage I-IIIA--preliminary report].
    Kosacka M; Korzeniewska A; Jankowska R
    Pol Merkur Lekarski; 2010 Feb; 28(164):117-21. PubMed ID: 20369739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.
    Mino N; Takenaka K; Sonobe M; Miyahara R; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Mar; 95(3):250-7. PubMed ID: 17323339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.